Literature DB >> 22231465

Successful use of second cord blood transplantation to achieve long-term remission in cord blood donor cell-derived AML harboring a FLT3-ITD and an NPM1 mutation.

K Chonabayashi, T Kondo, K Yamamoto, Y Tanaka, Y Nagai, M Hishizawa, A Takaori-Kondo.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22231465     DOI： 10.1038/bmt.2011.256

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  4 in total

1.  Donor cell-derived hematological malignancy: a survey by the Japan Society for Hematopoietic Cell Transplantation.

Authors:  M Kato; T Yamashita; R Suzuki; K Matsumoto; H Nishimori; S Takahashi; K Iwato; C Nakaseko; T Kondo; K Imada; F Kimura; T Ichinohe; Y Hashii; K Kato; Y Atsuta; S Taniguchi; T Fukuda
Journal:  Leukemia       Date:  2016-02-12       Impact factor: 11.528

2.  National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Subsequent Neoplasms Working Group Report.

Authors:  Lindsay M Morton; Wael Saber; K Scott Baker; A John Barrett; Smita Bhatia; Eric A Engels; Shahinaz M Gadalla; David E Kleiner; Steven Pavletic; Linda J Burns
Journal:  Biol Blood Marrow Transplant       Date:  2016-09-12       Impact factor: 5.742

Review 3.  Donor cell-derived leukemia after cord blood transplantation and a review of the literature: differences between cord blood and BM as the transplant source.

Authors:  H Shiozaki; K Yoshinaga; T Kondo; Y Imai; M Shiseki; N Mori; M Teramura; T Motoji
Journal:  Bone Marrow Transplant       Date:  2013-09-09       Impact factor: 5.483

4.  Jumping translocations of 1q in donor cell-derived myelodysplastic syndrome after cord blood transplantation: Case report and review of the literature.

Authors:  Toshinori Kondo; Taizo Tasaka; Risa Shimizu; Kiyohito Hayashi; Seiko Yamada; Hirofumi Fukuda; Tadashi Hirose; Asako Takeuchi; Fuminori Sano; Hirotoshi Tokunaga; Yoshiko Matsuhashi; Hideho Wada
Journal:  Mol Clin Oncol       Date:  2020-02-06
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.